Akari Therapeutics (AKTX) EBIT (2014 - 2026)
Akari Therapeutics recorded quarterly EBIT of -$15.8 million in Q1 2026, down 388.32% quarter-over-quarter from -$3.2 million in Q4 2025, and down 347.04% year-over-year from $6.4 million in Q1 2025.
Akari Therapeutics' EBIT history runs 13 years deep, the most recent figure standing at -$15.8 million for Q1 2026.
- In Q1 2026, EBIT fell 347.04% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$29.5 million (up 76.56% YoY), while the FY2025 annual figure was -$17.3 million, up 20.18% from the prior year.
- EBIT came in at -$15.8 million for Q1 2026 at Akari Therapeutics, down from -$3.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$2.5 million in Q3 2023 to a low of -$112.0 million in Q4 2024.
- A 5-year average of -$12.6 million and a median of -$5.1 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT plunged 2100.12% in 2024 and soared 97.12% in 2025, its largest moves.
- Akari Therapeutics' EBIT stood at -$5.8 million in 2022, then advanced by 12.49% to -$5.1 million in 2023, then slumped by 2100.12% to -$112.0 million in 2024, then jumped by 97.12% to -$3.2 million in 2025, then sank by 388.32% to -$15.8 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$15.8 million, -$3.2 million, and -$7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -445.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -3.23 Mn |
| Sep 30, 2025 | -7.40 Mn |
| Jun 30, 2025 | -3.12 Mn |
| Mar 31, 2025 | -3.53 Mn |
| Dec 31, 2024 | -111.99 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -7.45 Mn |
| Mar 31, 2024 | -5.99 Mn |
| Dec 31, 2023 | -5.09 Mn |
| Sep 30, 2023 | -2.51 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -4.59 Mn |
| Jun 30, 2022 | -5.82 Mn |
| Mar 31, 2022 | -5.24 Mn |
| Dec 31, 2021 | -20.46 Bn |
| Sep 30, 2021 | -1.46 Mn |
| Jun 30, 2021 | -4.33 Mn |
| Mar 31, 2021 | -5.55 Mn |
| Dec 31, 2020 | -6.90 Mn |
| Sep 30, 2020 | -246,883.00 |
| Jun 30, 2020 | -5.91 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -3.12 Mn |
| Jun 30, 2019 | -6.03 Mn |
| Mar 31, 2019 | 11,962.00 |
| Dec 31, 2018 | -4.73 Mn |
| Sep 30, 2018 | -2.99 Mn |
| Jun 30, 2018 | -7.98 Mn |
| Mar 31, 2018 | -4.31 Mn |
| Dec 31, 2017 | -13.61 Mn |
| Sep 30, 2017 | -8.54 Mn |
| Jun 30, 2017 | -7.35 Mn |
| Mar 31, 2017 | -8.28 Mn |
| Dec 31, 2016 | -9.85 Mn |
| Sep 30, 2016 | -6.02 Mn |
| Jun 30, 2016 | -7.52 Mn |
| Mar 31, 2016 | -3.85 Mn |
| Dec 31, 2015 | -4.29 Mn |
| Sep 30, 2015 | -23.33 Mn |
| Jun 30, 2015 | -1.31 Mn |
| Mar 31, 2015 | -1.65 Mn |
| Dec 31, 2014 | -1.11 Mn |
| Sep 30, 2014 | -218,029.00 |
| Jun 30, 2014 | -2.33 Mn |
| Mar 31, 2014 | -1.88 Mn |